Estévez-Arias Berta, Matalonga Leslie, Yubero Delia, Polavarapu Kiran, Codina Anna, Ortez Carlos, Carrera-García Laura, Expósito-Escudero Jesica, Jou Cristina, Meyer Stefanie, Kilicarslan Ozge Aksel, Aleman Alberto, Thompson Rachel, Luknárová Rebeka, Esteve-Codina Anna, Gut Marta, Laurie Steven, Demidov German, Yépez Vicente A, Beltran Sergi, Gagneur Julien, Topf Ana, Lochmüller Hanns, Nascimento Andres, Hoenicka Janet, Palau Francesc, Natera-de Benito Daniel
Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.
Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Eur J Hum Genet. 2025 Mar;33(2):239-247. doi: 10.1038/s41431-024-01699-4. Epub 2024 Sep 27.
Establishing a molecular diagnosis remains challenging in half of individuals with childhood-onset neuromuscular diseases (NMDs) despite exome sequencing. This study evaluates the diagnostic utility of combining genomic approaches in undiagnosed NMD patients. We performed deep phenotyping of 58 individuals with unsolved childhood-onset NMDs that have previously undergone inconclusive exome studies. Genomic approaches included trio genome sequencing and RNASeq. Genetic diagnoses were reached in 23 out of 58 individuals (40%). Twenty-one individuals carried causal single nucleotide variants (SNVs) or small insertions and deletions, while 2 carried pathogenic structural variants (SVs). Genomic sequencing identified pathogenic variants in coding regions or at the splice site in 17 out of 21 resolved cases, while RNA sequencing was additionally required for the diagnosis of 4 cases. Reasons for previous diagnostic failures included low coverage in exonic regions harboring the second pathogenic variant and involvement of genes that were not yet linked to human diseases at the time of the first NGS analysis. In summary, our systematic genetic analysis, integrating deep phenotyping, trio genome sequencing and RNASeq, proved effective in diagnosing unsolved childhood-onset NMDs. This approach holds promise for similar cohorts, offering potential improvements in diagnostic rates and clinical management of individuals with NMDs.
尽管进行了外显子组测序,但在半数患有儿童期起病的神经肌肉疾病(NMD)的个体中,建立分子诊断仍然具有挑战性。本研究评估了在未确诊的NMD患者中联合基因组方法的诊断效用。我们对58例患有未解决的儿童期起病的NMD且先前外显子组研究结果不确定的个体进行了深度表型分析。基因组方法包括三联体基因组测序和RNA测序。58例个体中有23例(40%)获得了基因诊断。21例个体携带致病性单核苷酸变异(SNV)或小插入和缺失,2例携带致病性结构变异(SV)。在21例确诊病例中,17例通过基因组测序在编码区或剪接位点鉴定出致病变异,另外4例需要RNA测序进行诊断。先前诊断失败的原因包括携带第二个致病变异的外显子区域覆盖度低,以及在首次二代测序分析时涉及尚未与人类疾病相关联的基因。总之,我们整合深度表型分析、三联体基因组测序和RNA测序的系统遗传学分析,在诊断未解决的儿童期起病的NMD方面被证明是有效的。这种方法对类似队列具有前景,有望提高NMD患者的诊断率和临床管理水平。